We’re bringing the latest in breast imaging to you.
COVID-19 significantly impacted annual screening mammograms, risking our chance to catch diseases early enough to start proper treatment. Fear and anxiety remain added barriers to screening, and a focus on patient experience is critical in connecting with women to take action in their breast health. The Senographe Pristina™ 3D digital mammography system is designed for patient experience and diagnostic confidence. We’re hitting the road to share with you how the enhanced patient comfort and innovative solutions offered through Pristina can impact all women, in an effort to increase screenings across the US.
Join us to explore our latest breast imaging innovations to help with early cancer detection and enable rapid diagnosis when your patients need it most.
Experience the latest in
patient-centric breast imaging.
Our cross-country roadshow will make 80 stops as we journey to bring our latest breast imaging innovations to a city near you. Join us to help empower women to take control of their own healthcare journeys one stop at a time.
SEE WHEN WE’LL BE IN YOUR AREADon’t miss your personalized tour of these innovative breast imaging solutions!
Senographe Pristina™
In collaboration with radiologists, technicians, and patients, GE Healthcare has developed an innovative mammography system tailored to individual needs—helping relieve patients of anxiety, making work easier for technicians, and enabling radiologists to make a more reliable, diagnosis. The result of our consistent, collaborative design process is the Senographe Pristina platform: patient comfort, reliability, and clarity for radiologists.
LEARN MORE
Pristina Dueta™
The industry’s first patient-operated compression device that makes patients feel more secure during mammography. Guided by technologist supervision, patients can now achieve the compression that is right for them. This new patient-assisted compression feature enables the patient to be an active participant in their exam, while helping to reduce anxiety associated with mammograms.1
LEARN MORE
SenoBright™ HD
A straightforward, alternative diagnostic exam that complements today’s breast care pathway, SenoBright HD delivers exceptionally clear images so you can give your patients a confident, accurate diagnosis faster. SenoBright HD, contrast enhanced mammography, is an excellent alternative to contrast-guided breast MRI, especially when MRI availability is limited and for patients for whom MRI is contraindicated. SenoBright HD provides high specificity to reduce false-positives and help prevent unnecessary exams and high sensitivity for more accurate breast cancer diagnosis.2
LEARN MORE
Serena Bright™ (NEW!)
With Serena Bright™ Contrast Assisted Biopsy, you no longer need to leave the mammography room to perform biopsies of contrast-identified lesions. The procedure can be performed in approximately 15 minutes and is not only fast, but also offers exceptional clinical reliability and accuracy without the need of an MRI.3
LEARN MORE
SensorySuite™
By focusing on the reasons why women avoid mammography, we designed SensorySuite to stimulate a women's senses to distract her from the perceived discomfort, pain, and anxiety of a mammogram. Enhance the experience you offer to your patient by letting her choose the environmental ambiance she prefers for her mammogram.
LEARN MORE
Invenia™ ABUS 2.0
GE Healthcare offers the first FDA-approved ultrasound supplemental screening technology that is specifically designed for detecting cancer in dense breast tissue. Compared to mammography alone, Invenia ABUS 2.0 imaging looks differently at dense breast tissue, providing a comprehensive view of the breast. This technology has demonstrated a 35.7% increase in cancer detection over mammography alone for these women.4
Supplemental imaging with Invenia ABUS 2.0 transforms breast care from reactive to proactive. Clinical research studies demonstrate that when used as an adjunct to mammography, small cancers visible only through ABUS were predominantly invasive and node-negative.4-5 Detecting them at this earlier stage has important prognostic implications and can reduce the cost of care.6
LEARN MORE
Your health and safety is our priority.
GE Healthcare is committed to providing a safe interactive experience during our Breast Imaging Roadshow as we navigate the impacts of COVID-19. We ask that if you are not feeling well, or have had known exposure to COVID, that you do not attend this interactive session.
Prior to entry into the session, GE Healthcare will be performing active monitoring and screening the temperature of every attendee. Face coverings will be required and we ask that physical distancing be maintained when possible.
We ask for your continued cooperation and appreciate your support in adhering to GE Healthcare requirements. We are all in this together.
Join the conversation
#dontskip
Sources:
1. IPSOS Patient Satisfaction Study sponsored by GE Healthcare, conducted with 160 patients who used patient assisted compression across 2 sites in Europe, February 2017.
2. M Daniaux, T De Zordo, et al. Dual-energy contrast-enhanced spectral mammography (CESM). Arch Gynecol Obstet. 2015;292(4):739–747.
3. Data on file 2020 GE Healthcare; time from first to last image
4. FDA PMA P110006 summary of safety and effectiveness.
5. B Wilczek, H. Wilczek, et al. Adding 3D automated breast ultrasound to mammography screening in women with heterogeneously and extremely dense breasts: Report from a hospital-based, high-volume, single-center breast cancer screening program. European Journal of Radiology. 2016;85(9):1554–1563. DOI: https://doi.org/10.1016/j.ejrad.2016.06.004.
6. H Blumen, et al. Comparison of treatment costs for Breast Cancer, by tumor stage and type of service. Am Health Drug Benefits. 2016;9(1):23–32.
Not commercially available in all markets. Check with your local GE Healthcare representative for availability in your country.
© 2021 General Electric Company. All rights reserved.
GE, GE Monogram, Inevenia, SenoBright, Serena Bright, Senographe Pristina are trademarks of General Electric Company.
JB05740US
